MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)

Inclusion Criteria: * Diagnosis of relapsing-remitting multiple sclerosis (RRMS) * ability to consent and a written approval * First acute ON attack to the fit eye within 30 days before screening * Age 18 - 55 years at screening * EDSS ≤ 6.0 * No MS Attack except for ON in the last 30 days before screening * No immunomodulatory therapy for at least three Months (before randomization), or * strong immunomodulatory therapy with interferon beta or glatiramer acetate for at least 6 months * visus in the affected eye at least 0.1 * latency of Conventional VEP in the affected eye * = 115 ms or difference\> = 15 ms to the opposite side at a Study at least 4 but no more than 6 weeks after Onset of clinical symptoms * At least 2 T2 lesions typical of MS in a previous MRI Exclusion Criteria: * other MS course than RRMS * any condition which could interfere or prevent the MRI study or other investigations * known allergy or intolerance, or other contraindication against Gd-DTPA * Patients with known contraindications to treatment with fingolimod (Gilenya ®) or interferon beta-1b Extavia ® * Competing diseases which could affect visual functions such as diabetic, retinopathy, glaucoma, retinal detachment